Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin B3 + Tislelizumab + Chemo in Antibiotic-Exposed Bladder Cancer
NCT07119996Phase 1Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cannabidiol in urothelial carcinoma of the bladder (UC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Aug 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
urothelial carcinoma of the bladder (UC)
Beyond the preview
Go deeper on NCT07119996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07119996.